Point72 Asset Management
HOWL icon

Point72 Asset Management’s Werewolf Therapeutics HOWL Stock Holding History

Point72 Asset Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,200
Closed -$127K – 2145
2024
Q2 		$127K Buy
+52,200
New +$251K ﹤0.01% 1680

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management's HOWL Position: Q1 2026 in Review

Point72 Asset Management sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 14,483 shares — an estimated $9.18K sold.

Point72 Asset Management first reported a position in HOWL in Q2 2024 and held it in 3 quarters. The position peaked at $780K in Q2 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Point72 Asset Management reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 14,483 Werewolf Therapeutics shares in Q1 2026, an estimated $9.18K.
  • Point72 Asset Management first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 Asset Management's Werewolf Therapeutics position peaked at $780K in Q2 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.